Amgen Inc Price, Chart & Factor Exposure
Free Data & Analytics AccessLatest earnings: November 3, 2026 results vs estimates
Amgen Inc Forecast
Amgen Inc short-term momentum is strongly positive (up over 4 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (8 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 25.4% a year, a typical one-standard-deviation range is 444.24–477.22 over a week, 426.93–494.53 over a month and 343.64–577.82 over a year. (Signals as of 1 Nov 2026.)
Amgen Inc Price Chart
Amgen Inc Factors
YoY +2.6%
YoY +27.1%
YoY −7.8%
YoY +16.7%
YoY +18.5%
YoY −39.6%
YoY −2.5%
YoY −22.7%
YoY +37.5%
YoY −9.6%
YoY −17.7%
YoY +15.6%
YoY +21.8%
YoY +33.8%
YoY −33.7%
YoY 0.0%
YoY +36.9%
Amgen Inc fundamentals: income statement, balance sheet & cash flow
Amgen Inc reported revenue of $36.74bn and net income of $7.71bn in FY2025, the year ended 31 December 2025 — revenue up 9.9% and net income up 88.5% on the prior year. Free cash flow was $8.10bn. These figures are as reported in the filings, not restated: 41 fiscal years and 165 quarters of history, back to December 1985. 173 FINRA short-interest settlements are published alongside them, back to June 2019.
| USD billions | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
| Revenue | 36.74 | 33.42 | 28.19 | 26.32 | 25.98 |
| Cost of revenue | 10.73 | 12.86 | 8.45 | 6.41 | 6.45 |
| Gross profit | 26.01 | 20.57 | 19.74 | 19.92 | 19.53 |
| Research & development | 6.97 | 5.96 | 4.78 | 4.43 | 6.32 |
| Operating income | 9.08 | 7.26 | 7.90 | 9.57 | 7.64 |
| EBITDA | 16.90 | 13.36 | 7.90 | 12.17 | 11.30 |
| Interest expense | 2.76 | 3.16 | 2.88 | 1.41 | 1.20 |
| Pre-tax income | 8.98 | 4.61 | 7.86 | 7.35 | 6.70 |
| Income tax | 1.27 | 0.52 | 1.14 | 0.79 | 0.81 |
| Net income | 7.71 | 4.09 | 6.72 | 6.55 | 5.89 |
Download Amgen Inc fundamentals
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.AMGN.NASDAQ&statement=all&freq=a&format=csv&years=10
Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.
Research on Amgen Inc
Explore MacroFinance macro & markets research and analysis.
Amgen Inc Trading Strategies
58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to Amgen Inc; 28 of them are invested now. Strategies currently invested are listed first.
| Strategy | Style | Rebalance | Now in SPY, XLV | CAGR | Sharpe | Max DD |
|---|---|---|---|---|---|---|
| Tactical Permanent Portfolio | Conservative | Monthly | Premium · upgrade to view | |||
| Zakamulin and Giner's Optimal Trend Following | Moderate | Monthly | Premium · upgrade to view | |||
| Movement Capital's Composite Strategy | Moderate | Monthly | Premium · upgrade to view | |||
| Harry Browne's Permanent Portfolio | Conservative | Monthly | 25% | 7.0% | 0.96 | -17.2% |
| Keller and Van Putten's Flexible Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Ned Davis' Three Way Model | Moderate | Monthly | Premium · upgrade to view | |||
| 60_40 Benchmark | Moderate | Monthly | 60% | 8.2% | 0.93 | -29.5% |
| Dick Stoken's Active Combined Asset (ACA) - Monthly Trading | Moderate | Monthly | Premium · upgrade to view | |||
| PortfolioCharts' Golden Butterfly | Moderate | Monthly | 20% | 7.4% | 0.91 | -18.0% |
| US Cross-Asset Momentum | Moderate | Monthly | Premium · upgrade to view | |||
Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.
From creators
- P4 Demo Momentum by admin
- strategyx by admin
About Amgen Inc (United States)
Amgen Inc is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).
Last updated: November 22, 2026
More on Amgen Inc
Frequently asked questions
What is Amgen Inc?
What is the latest Amgen Inc price?
Is Amgen Inc in an uptrend?
How volatile is Amgen Inc?
What factors affect Amgen Inc?
Which trading strategies trade Amgen Inc?
Where can I download free Amgen Inc historical data?
Free Amgen Inc historical data (last 10 years)
Browse or instantly download the last 10 years of Amgen Inc daily price history. A free account unlocks the full history, an Excel export with factors, and API access.
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.AMGN.NASDAQ&format=csv&years=10
| Date | Close |
|---|---|
| 2026-11-20 | 435.64 |
| 2026-11-19 | 436.3 |
| 2026-11-18 | 441.341 |
| 2026-11-17 | 455.3 |
| 2026-11-16 | 459.665 |
| 2026-11-13 | 462.996 |
| 2026-11-12 | 464.378 |
| 2026-11-11 | 465.422 |
| 2026-11-10 | 462.558 |
| 2026-11-09 | 462.558 |
About this stock
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is he
See how this market's returns behaved when a factor was in a given state, for example when Momentum was strong or bond yields were above 4%, and compare that with all periods.
Reading the chart
- Each bar is a return bucket; its height is the share of periods that landed there.
- All periods: every return in the date range.
- Matching periods: only the periods where all your filters were true. If orange shifts right of the grey, returns were better in that regime.
- Each period's return is the return over the following day, week or month (set by Timeframe), measured from the day the factor was read, so there is no look-ahead.
Adding a filter
- Factor: grouped the same way as the Factors section on this page (Quantitative, Country, Sector, …). Locked factors are listed but greyed out.
- Criteria: greater (>), greater or equal (≥), equal (=), smaller or equal (≤), smaller (<) or between two values.
- Value: depends on the factor.
- Momentum and Trend are signals from −1 to +1, picked as −100 to +100 in steps of 25.
- Mean Reversion is a z-score of price against its 250-day mean, picked in σ from −3 to +3.
- Everything else is a number you type. The line under the box shows the latest reading and its typical range over the last 10 years.
Add several filters to combine conditions; a period must pass every one. Narrow the window with the From/To dates or the 1Y / 5Y / 10Y / MAX buttons; Clear resets filters and dates.
Return statistics
- Unfiltered vs Filtered: all periods vs matching periods.
- Average return, Std dev and Sharpe are annualised (252 days, 52 weeks, 12 months, 6 two-month periods, 4 quarters).
- Maximum drawdown compounds non-overlapping periods; in the Filtered column it assumes you held only while the condition was true.
- Min, 25th percentile, median, 75th percentile and max are per period, not annualised.